NCT07276750 Coaching and Leadership in Autism Support Settings
| NCT ID | NCT07276750 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of California, Los Angeles |
| Condition | Autism Spectrum Disorder (ASD) |
| Study Type | INTERVENTIONAL |
| Enrollment | 373 participants |
| Start Date | 2026-02-01 |
| Primary Completion | 2030-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 373 participants in total. It began in 2026-02-01 with a primary completion date of 2030-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Schools serve a large number of autistic children, yet face two critical gaps that stifle the delivery of evidence-based practices: 1) an intervention gap characterized by limited availability of evidence-based practices educators can use to address externalizing behaviors when they occur in the classroom; and 2) an implementation gap consisting of insufficient evidence-based practice fidelity and sustainment over time. To address these gaps, this project proposes a hybrid type 2 effectiveness-implementation trial that simultaneously tests: 1) the clinical effectiveness of an efficient, educator-delivered clinical intervention to reduce autistic children's externalizing behaviors (Research Units in Behavioral Interventions in Educational Settings; RUBIES), and 2) the implementation effectiveness of an organizational implementation strategy designed specifically to enhance sustainment of evidence-based practices in public schools (Helping Educational Leaders Mobilize evidence; HELM). Consistent with the National Institute of Mental Health (NIMH)'s experimental therapeutics approach, the project also examines the mechanisms through which RUBIES impacts clinical outcomes and through which HELM influences implementation outcomes. The proposed study directly responds to high priority research areas of the US Department of Health and Human Services Interagency Autism Coordinating Committee's Strategic Plan for Autism Research, which calls for expanded research on the translation of proven-efficacious interventions into the community, NIMH Strategic Priority 3.3 to test interventions for effectiveness in community practice settings, and NIMH Strategic Priority 4.2 to expedite adoption, sustained implementation, and continuous improvement of evidence-based mental health services. If successful, this study will have substantial public health impact because it will produce an effective intervention for a prevalent problem among a high impact population in schools across the United States of America and will determine how to sustain this (and other) intervention(s) with high fidelity, to the betterment of health.
Eligibility Criteria
Inclusion Criteria: * Special or general education teachers, paraeducators, and other staff who provide direct instruction and/or behavioral support to autistic children during the school day (e.g., speech therapist, school psychologist). * Autistic children with: * a documented autism spectrum disorder diagnosis via school records (i.e., Individualized Education Program; IEP) * are enrolled with a participating educator * are in grades K-5 * ages 5-12 * Sutter Eyberg Student Behavior Inventory-Revised (SESBI-R) total score \>=101 * EDI sum score of \>=8 at baseline Exclusion Criteria: * SESBI-R total score \<101 (i.e. T score 51+) * EDI sum score \<8
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07276750 clinical trial?
This trial is open to participants of all sexes, aged 5 Years or older, studying Autism Spectrum Disorder (ASD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07276750 currently recruiting?
Yes, NCT07276750 is actively recruiting participants. Contact the research team at locke@seis.ucla.edu for enrollment information.
Where is the NCT07276750 trial being conducted?
This trial is being conducted at Los Angeles, United States.
Who is sponsoring the NCT07276750 clinical trial?
NCT07276750 is sponsored by University of California, Los Angeles. The trial plans to enroll 373 participants.